Výsledky vyhledávání - "Timothy Mant"

Akademický článek

Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease

Autor: Paul Telfer, Irene Agodoa, Kathleen M. Fox, Laurie Burke, Timothy Mant, Marzena Jurek, Margaret Tonda, Josh Lehrer-Graiwer

Publikováno v: Hematology Reports, Vol 10, Iss 2 (2018)

For many patients with sickle cell disease (SCD), jaundice is a significant clinical disease manifestation that impacts on patient well-being. We report a case of a patient with SCD and chronic jaundice treated with voxelotor (GBT440), a novel small

Externí odkaz: https://doaj.org/article/5a6a888f058a4f77855c543547925246

Zobrazit plný text záznamu

A phase 1/2 ascending dose study and open-label extension study of voxelotor in patients with sickle cell disease

Autor: Vincent Siu, Timothy Mant, Mira Patel, Noel Landsman, Joshua Lehrer-Graiwer, Moji Awogbade, Kobina Dufu, John B. Porter, Daniel D. Gretler, Athiwat Hutchaleelaha, Sandra V. Dixon, Claire Hemmaway, Paul Telfer, D. Mark Layton, Jo Howard, Margaret Tonda

Publikováno v: Blood. 133:1865-1875

New treatments directly targeting polymerization of sickle hemoglobin (HbS), the proximate event in the pathophysiology of sickle cell disease (SCD), are needed to address the severe morbidity and early mortality associated with the disease. Voxeloto

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::7890326c7b563b083e7615d4cfa0cca0
https://doi.org/10.1182/blood-2018-08-868893

Zobrazit plný text záznamu

Pharmacokinetics and pharmacodynamics of voxelotor (GBT440) in healthy adults and patients with sickle cell disease

Autor: Athiwat Hutchaleelaha, Timothy Mant, Elizabeth Allen, Donna Oksenberg, Josh Lehrer-Graiwer, Mira Patel, Carla Washington, Daniel D. Gretler, Vincent Siu

Publikováno v: British Journal of Clinical Pharmacology

Aims Voxelotor (previously GBT440) is a haemoglobin (Hb) modulator that increases Hb-oxygen affinity, thereby reducing Hb polymerization and sickling of red blood cells (RBCs), being developed as a once-daily oral drug to treat sickle cell disease (S

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::6608703bfd75b38215bf71b9bb524287
https://doi.org/10.1111/bcp.13896

Zobrazit plný text záznamu

Treatment with IMR-687, a Highly Selective PDE9 Inhibitor, Increases HbF and Reduces VOCs in Adults with Sickle Cell Disease in a Long-Term, Phase 2a, Open-Label Extension Study

Autor: Joseph Yen, Filipa Barroso, Kenneth M. Attie, Karen Tang, Constance M Barysauskas, Timothy Mant, Rahul Ballal, James Mason, Biree Andemariam, Perla Eleftheriou, Gershwin Blyden, Lanetta Bronté-Hall, Sanne Lugthart

Publikováno v: Blood. 138:2046-2046

Introduction IMR-687 (tovinontrine) is a highly selective phosphodiesterase 9 (PDE9) inhibitor being developed as an orally administered therapy for patients with sickle cell disease (SCD) and beta-thalassemia. IMR-687 increases intracellular cGMP le

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::dd42d18010d4493cf45b5ce70d79527f
https://doi.org/10.1182/blood-2021-149536

Zobrazit plný text záznamu

Benefits and Safety of Long-Term Use of IMR-687 As Monotherapy or in Combination with a Stable Dose of Hydroxyurea (HU) in 2 Adult Sickle Cell Patients

Autor: Biree Andemariam, Rahul Ballal, Eleanor Lisbon, Jo Howard, Robert Ward Hagar, Timothy Mant, James Mason, Blyden Gershwin, Sanne Lugthart, Henry Fok, Joelle Lufkin, Lanetta Bronté-Hall, Perla Eleftheriou

Publikováno v: Blood. 136:29-30

Study Background IMR-687 is an inhibitor of phosphodiesterase 9 intended to treat sickle cell disease (SCD) by stimulating the production of fetal hemoglobin (HbF). IMR-SCD-102-EXT is an open-label extension (OLE) study of an ongoing Ph 2a, randomize

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::3e917b31cfab0dd89383b979a0f07d05
https://doi.org/10.1182/blood-2020-140540

Zobrazit plný text záznamu

An S-warfarin and AZD1981 interaction:in vitroand clinical pilot data suggest the N-deacetylated amino acid metabolite as the primary perpetrator

Autor: Clive Brealey, Pär Nordell, Petter Svanberg, Wolfgang Kühn, Barry Jones, Marie Brännström, Ken Grime, Timothy Mant, Rikard Pehrson, Michael Gillen

Publikováno v: British Journal of Clinical Pharmacology. 83:381-392

Aim AZD1981 is an orally bioavailable chemoattractant receptor-homologous molecule expressed on Th2 cells (CRTh2) receptor antagonist progressed to phase II trials for the treatment of allergic asthma. Previously performed in vitro human hepatocyte i

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_________::c6a6c19719f2544adb8e8990d2bebc0a
https://doi.org/10.1111/bcp.13102

Zobrazit plný text záznamu

Safety and patient response as indicated by biomarker changes to binding immunoglobulin protein in the phase I/IIA RAGULA clinical trial in rheumatoid arthritis

Autor: Alexandra Vincent, A T Prevost, Joana C. Vasconcelos, Christopher Hall, Timothy Mant, Toby Garrood, Valerie Corrigall, Elizabeth Allen, Khaldoun Chaabo, Bruce Kirkham, Gabriel S. Panayi

Publikováno v: Rheumatology. 55:1993-2000

Objectives Binding immunoglobulin protein (BiP) is a human endoplasmic reticulum-resident stress protein. In pre-clinical studies it has anti-inflammatory properties due to the induction of regulatory cells. This randomized placebo-controlled, dose a

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::143099c969aa8e55c9fc7b3fdbecbd3e
https://doi.org/10.1093/rheumatology/kew287

Zobrazit plný text záznamu

Impact of voxelotor (GBT440) on unconjugated bilirubin and jaundice in sickle cell disease

Autor: Timothy Mant, Margaret Tonda, Josh Lehrer-Graiwer, Irene Agodoa, Marzena Jurek, Kathleen M. Fox, Laurie B. Burke, Paul Telfer

Publikováno v: Hematology Reports, Vol 10, Iss 2 (2018)
Hematology Reports

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::71325be1727329080114485f9fdb3589
https://www.pagepress.org/journals/index.php/hr/article/view/7643

Zobrazit plný text záznamu

Group II metabotropic glutamate receptor agonist prodrugs LY2979165 and LY2140023 attenuate the functional imaging response to ketamine in healthy subjects

Autor: Vasileia Kotoula, Anne Schmechtig, Paul D. Morrison, Claire Brittain, Mitul A. Mehta, Juliet McColm, Thomas A Pollak, Steven Williams, Adam J. Schwarz, Kimberley Jackson, Bruce J Kinon, Timothy Mant, Sitra Tauscher-Wisniewski

Publikováno v: Psychopharmacology. 235(7)

Aberrant glutamate neurotransmission, and in particular dysfunction of the N-methyl-D-aspartate receptor (NMDAR), has been implicated in psychiatric disorders and represents a novel therapeutic target. Low-dose administration of the NMDA antagonist k

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::028abf11a52446ca4ad04ae1d221fc3b
https://pubmed.ncbi.nlm.nih.gov/29564482

Zobrazit plný text záznamu

A phase 1 study of prasugrel in patients with sickle cell disease: Effects on biomarkers of platelet activation and coagulation

Autor: Andrew L. Frelinger, Joseph A. Jakubowski, Stipo Jurcevic, Neehar Gupta, Chunmei Zhou, Jo Howard, Timothy Mant, Christopher D. Payne, D. Richard Lachno, Kenneth J. Winters

Publikováno v: Thrombosis Research. 133:190-195

Introduction Prasugrel, a P2Y12 adenosine diphosphate (ADP) receptor antagonist effectively inhibits ADP-mediated platelet activation and aggregation, and may be useful in reducing vaso-occlusive crises in sickle cell disease (SCD). In this study, we

Externí odkaz: https://explore.openaire.eu/search/publication?articleId=doi_dedup___::2c3cf109849ff65fcee254540a7d127b
https://doi.org/10.1016/j.thromres.2013.12.008

Zobrazit plný text záznamu

Vyhledávací nástroje:

Upřesnit hledání